These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 2757009

  • 1. Ferrokinetic study of splenic erythropoiesis: relationships among clinical diagnosis, myelofibrosis, splenomegaly, and extramedullary erythropoiesis.
    Beguin Y, Fillet G, Bury J, Fairon Y.
    Am J Hematol; 1989 Oct; 32(2):123-8. PubMed ID: 2757009
    [Abstract] [Full Text] [Related]

  • 2. Analysis of extramedullary erythropoiesis in the spleen by a semiquantitative method using indium-111.
    Rojer RA, Mulder NH, Nieweg HO, Edin MR, Beekhuis H, Piers DA, Woldring MG.
    Acta Med Scand; 1978 Oct; 203(6):481-6. PubMed ID: 665315
    [Abstract] [Full Text] [Related]

  • 3. Quantitative studies of splenic erythropoiesis in polycythaemia vera and myelofibrosis.
    Pettit JE, Lewis SM, Williams ED, Grafton CA, Bowring CS, Glass HI.
    Br J Haematol; 1976 Nov; 34(3):465-75. PubMed ID: 990184
    [Abstract] [Full Text] [Related]

  • 4. Development of polycythaemia vera in a patient with myelofibrosis.
    Dokal I, Pagliuca A, Deenmamode M, Mufti GJ, Lewis SM.
    Eur J Haematol; 1989 Jan; 42(1):96-8. PubMed ID: 2914600
    [Abstract] [Full Text] [Related]

  • 5. [Ineffective erythropoiesis in myeloid splenomegaly: the 59Fe test, bone marrow histologic and cytologic data].
    Charbord P, Caillou B, Lafleur M, Parmentier C.
    Nouv Rev Fr Hematol (1978); 1978 Nov 25; 20(3):443-53. PubMed ID: 754175
    [Abstract] [Full Text] [Related]

  • 6. Splenectomy in chronic myeloid leukemia and myelofibrosis with myeloid metaplasia.
    Mesa RA, Elliott MA, Tefferi A.
    Blood Rev; 2000 Sep 25; 14(3):121-9. PubMed ID: 10986148
    [Abstract] [Full Text] [Related]

  • 7. The splenomegaly of myeloproliferative disorders: effects on blood volume and red blood count.
    Zhang B, Lewis SM.
    Eur J Haematol; 1989 Mar 25; 42(3):250-3. PubMed ID: 2924887
    [Abstract] [Full Text] [Related]

  • 8. Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia.
    Tefferi A.
    Semin Hematol; 1999 Jan 25; 36(1 Suppl 2):3-8. PubMed ID: 9930550
    [Abstract] [Full Text] [Related]

  • 9. Bone marrow histopathology and biological markers as specific clues to the differential diagnosis of essential thrombocythemia, polycythemia vera and prefibrotic or fibrotic agnogenic myeloid metaplasia.
    Michiels JJ.
    Hematol J; 2004 Jan 25; 5(2):93-102. PubMed ID: 15048058
    [Abstract] [Full Text] [Related]

  • 10. Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders.
    Cortes J, Giles F, O'Brien S, Thomas D, Albitar M, Rios MB, Talpaz M, Garcia-Manero G, Faderl S, Letvak L, Salvado A, Kantarjian H.
    Cancer; 2003 Jun 01; 97(11):2760-6. PubMed ID: 12767088
    [Abstract] [Full Text] [Related]

  • 11. SPLENECTOMY FOR AGNOGENIC MYELOID METAPLASIA AND MYELOFIBROSIS.
    FISHMAN N, BALLINGER WF.
    Arch Surg; 1965 Feb 01; 90():240-6. PubMed ID: 14232953
    [No Abstract] [Full Text] [Related]

  • 12. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
    Bellucci S, Michiels JJ.
    Semin Thromb Hemost; 2006 Jun 01; 32(4 Pt 2):381-98. PubMed ID: 16810614
    [Abstract] [Full Text] [Related]

  • 13. [Chronic myeloproliferative diseases].
    Sréter L.
    Orv Hetil; 1998 Jul 26; 139(30):1779-83. PubMed ID: 9718944
    [Abstract] [Full Text] [Related]

  • 14. Myeloproliferative disorders. Classification and diagnostic features with special emphasis on chronic myelogenous leukemia and agnogenic myeloid metaplasia.
    Hyun BH, Gulati GL, Ashton JK.
    Clin Lab Med; 1990 Dec 26; 10(4):825-38. PubMed ID: 2272176
    [Abstract] [Full Text] [Related]

  • 15. The splenomegaly of myeloproliferative and lymphoproliferative disorders: splenic cellularity and vascularity.
    Zhang B, Lewis SM.
    Eur J Haematol; 1989 Jul 26; 43(1):63-6. PubMed ID: 2767243
    [Abstract] [Full Text] [Related]

  • 16. An addition to geographic hematology: chronic myeloproliferative diseases are infrequent in Mexican Mestizos.
    Ruiz-Argüelles GJ, López-Martínez B, Lobato-Mendizábal E, Ruiz-Delgado GJ.
    Int J Hematol; 2002 Jun 26; 75(5):499-502. PubMed ID: 12095150
    [Abstract] [Full Text] [Related]

  • 17. Understanding Splenomegaly in Myelofibrosis: Association with Molecular Pathogenesis.
    Song MK, Park BB, Uhm JE.
    Int J Mol Sci; 2018 Mar 18; 19(3):. PubMed ID: 29562644
    [Abstract] [Full Text] [Related]

  • 18. [Study of splenic erythropoiesis with radioisotopes in polycythemia vera complicated by myelosclerosis. (Study of 5 cases)].
    Vilcu A, Xenakis A, Hossu T, Câmpeanu L, Marcu I, Teitel P.
    Med Interna (Bucur); 1973 Sep 18; 25(9):1117-26. PubMed ID: 4792532
    [No Abstract] [Full Text] [Related]

  • 19. Splenic irradiation as a component of a reduced-intensity conditioning regimen for hematopoietic stem cell transplantation in myelofibrosis with massive splenomegaly.
    Ito T, Akagi K, Kondo T, Kawabata H, Ichinohe T, Takaori-Kondo A.
    Tohoku J Exp Med; 2012 Dec 18; 228(4):295-9. PubMed ID: 23117264
    [Abstract] [Full Text] [Related]

  • 20. Diagnostic value of bone marrow imaging with 111indium-transferrin and 99m technetium-colloids in myelofibrosis.
    Arrago JP, Rain JD, Vigneron N, Poirier O, Chomienne C, D'Agay MF, Najean Y.
    Am J Hematol; 1985 Mar 18; 18(3):275-82. PubMed ID: 3976644
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.